Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I double-blind randomized study of single-dose AKP-021 in healthy Japanese male adults
jRCT2071240097Phase 1Completed
- Sponsor
- ASKA Pharmaceutical Holdings Co., Ltd.
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AKP-021 (4 arms), sponsored by ASKA Pharmaceutical Holdings Co., Ltd. Primary endpoints: Safety, Pharmacokinetics of AKP-021 and 1 more. Started Feb 2025; status: completed.
02
Drugs
AKP-021
Beyond the preview
Go deeper on jRCT2071240097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240097.